Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine versus beta blockers for rate control in permanent atrial fibrillation
IRCT20241212064032N1Phase 3Completed
- Sponsor
- Chaudhry Pervaiz Elahi Institute of Cardiology
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of ivabradine and carvedilol in Atrial fibrillation (AFib) (2 arms), sponsored by Chaudhry Pervaiz Elahi Institute of Cardiology. Primary endpoint: Heart rate. Started Feb 2025; status: completed.
02
Drugs
ivabradinecarvedilol
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20241212064032N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241212064032N1.